{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T06:51:09Z","timestamp":1768459869656,"version":"3.49.0"},"reference-count":16,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T00:00:00Z","timestamp":1672012800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Muscle and Nerve"],"published-print":{"date-parts":[[2023,2]]},"abstract":"Abstract<\/jats:title>Introduction\/Aims<\/jats:title>Up to 25% of patients with myasthenia gravis (MG) have refractory disease despite trials of multiple immunosuppressants. Several case series describe acetylcholine receptor antibody\u2010positive (AChR) MG patients treated with autologous hematopoietic stem cell transplant (HSCT). In this report, we describe three patients with anti\u2010muscle\u2010specific kinase (MuSK) MG treated with HSCT.<\/jats:p><\/jats:sec>Methods<\/jats:title>We included all patients who had undergone HSCT with anti\u2010MuSK myasthenia gravis identified through the records of the Alberta Blood and Marrow Transplant Program. We collected demographic and clinical data including validated MG scales as well as questionnaire data.<\/jats:p><\/jats:sec>Results<\/jats:title>All 3 patients had severe disease (Myasthenia Gravis Foundation of America score IVb\u2010V) and were refractory to multiple treatments, including rituximab. All patients improved with no clinical manifestations or mild symptoms and remained as such for 2, 3.5, and 5.5\u00a0y. Adverse events ranged from treatable infections and transient dyspnea to persistent fatigue and premature menopause. The average worst Myasthenia Gravis Activities of Daily Living (MG\u2010ADL) scores improved from 14.7 before to 0.3 after HSCT. The mean worst Myasthenia Gravis Quality of Life Questionnaire (MG\u2010QoL15) scores improved from 26.7 to 0. All patients reported they would undergo transplant again for their MG.<\/jats:p><\/jats:sec>Discussion<\/jats:title>We describe three patients with anti\u2010MuSK MG treated with HSCT, all of whom became symptom free from MG with a tolerable side effect profile. In patients with severe refractory anti\u2010MuSK MG, it may be reasonable to consider HSCT.<\/jats:p><\/jats:sec>","DOI":"10.1002\/mus.27772","type":"journal-article","created":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T09:49:28Z","timestamp":1671270568000},"page":"154-157","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Autologous hematopoietic stem cell transplant for the treatment of refractory myasthenia gravis with anti\u2010muscle<\/scp> specific kinase antibodies"],"prefix":"10.1002","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9574-1412","authenticated-orcid":false,"given":"Benjamin","family":"Beland","sequence":"first","affiliation":[{"name":"Division of Neurology, Department of Clinical Neurosciences, Cumming School of Medicine University of Calgary Calgary Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Hahn","sequence":"additional","affiliation":[{"name":"Division of Neurology, Department of Clinical Neurosciences, Cumming School of Medicine University of Calgary Calgary Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kareem","family":"Jamani","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Cumming School of Medicine University of Calgary Calgary Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameer","family":"Chhibber","sequence":"additional","affiliation":[{"name":"Division of Neurology, Department of Clinical Neurosciences, Cumming School of Medicine University of Calgary Calgary Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"White","sequence":"additional","affiliation":[{"name":"Division of Neurology, Department of Clinical Neurosciences, Cumming School of Medicine University of Calgary Calgary Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harold","family":"Atkins","sequence":"additional","affiliation":[{"name":"Transplant and Cell Therapy Program The Ottawa Hospital Ottawa Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Storek","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Cumming School of Medicine University of Calgary Calgary Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,12,26]]},"reference":[{"issue":"6","key":"e_1_2_9_2_1","first-page":"1767","article-title":"Myasthenia gravis and congenital Myasthenic syndromes","volume":"25","author":"Ciafaloni E","year":"2019","journal-title":"Continuum"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.10.034"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2016.0113"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2016.09.020"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2018.11.008"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1201\/9781315151366-60"},{"key":"e_1_2_9_8_1","volume-title":"Neurology","author":"Burt R","year":"2004"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-4975(00)01595-2"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.52.7.1487"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25198"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25597"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-316271"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.17986"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2012.06.003"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2009.28"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-035766"}],"container-title":["Muscle & Nerve"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mus.27772","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/mus.27772","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mus.27772","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T09:48:59Z","timestamp":1692438539000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mus.27772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,26]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1002\/mus.27772"],"URL":"https:\/\/doi.org\/10.1002\/mus.27772","archive":["Portico"],"relation":{},"ISSN":["0148-639X","1097-4598"],"issn-type":[{"value":"0148-639X","type":"print"},{"value":"1097-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,26]]},"assertion":[{"value":"2022-06-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}